Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

被引:31
|
作者
McClung, M. R. [1 ]
Balske, A. [2 ]
Burgio, D. E. [3 ]
Wenderoth, D. [4 ]
Recker, R. R. [5 ]
机构
[1] Oregon Osteoporosis Ctr, Portland, OR 97213 USA
[2] Abbott Labs, Abbott Pk, IL 60064 USA
[3] Procter & Gamble Co, Mason, OH USA
[4] Warner Chilcott Deutschland GmbH, Weiterstadt, Germany
[5] Creighton Univ, Osteoporosis Res Ctr, Omaha, NE 68178 USA
关键词
Bone mineral density; Delayed-release; Enteric-coated; Histomorphometry; Osteoporosis; Risedronate; Weekly; LONG-TERM RISEDRONATE; NONVERTEBRAL FRACTURES; BISPHOSPHONATE THERAPY; VERTEBRAL FRACTURES; BONE QUALITY; WOMEN; ALENDRONATE; EFFICACY; ARCHITECTURE; RISK;
D O I
10.1007/s00198-012-2175-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bone mineral density response to once weekly delayed-release formulation of risedronate, given before or following breakfast, was non-inferior to that seen with traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient dosing regimen for oral bisphosphonate therapy that might avoid poor compliance. This 2-year, randomized, controlled, non-inferiority study assessed the efficacy and safety of a delayed-release (DR) 35-mg weekly oral formulation of risedronate that allows subjects to take their weekly risedronate dose before or immediately after breakfast. Results from the first year of the study were published previously (McClung et al. Osteoporos Int 23(1):267-276, 2012); we now report the final results after 2 years. Women with postmenopausal osteoporosis were randomly assigned to receive risedronate 5 mg immediate-release (IR) daily (n = 307) at least 30 min before breakfast, or risedronate 35 mg DR weekly, either immediately following breakfast (FB, n = 307) or at least 30 min before breakfast (BB, n = 308). Bone mineral density (BMD), bone turnover markers (BTMs), fractures, adverse events, and bone histomorphometry were evaluated. A total of 248 subjects (80.8 %) in the IR daily group, 234 subjects (76.2 %) in the DR FB weekly group, and 240 subjects (77.9 %) in the DR BB weekly group completed the 2-year study. After 2 years of treatment, BMD increases at the lumbar spine and total hip with the weekly DR doses similar to or greater than that with the IR daily dose. Decreases in BTMs were similar or significantly lower in the DR groups. Bone histomorphometry results did not differ among the DR weekly and the IR daily formulations. The three regimens were similarly well tolerated. Risedronate 35 mg DR weekly is as effective and as well tolerated as risedronate 5 mg IR daily, and will allow subjects to take their weekly risedronate dose immediately after breakfast.
引用
收藏
页码:301 / 310
页数:10
相关论文
共 50 条
  • [1] Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
    M. R. McClung
    A. Balske
    D. E. Burgio
    D. Wenderoth
    R. R. Recker
    Osteoporosis International, 2013, 24 : 301 - 310
  • [2] Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation
    Kinov, Plamen
    Boyanov, Mihail
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2012, 4 : 167 - 174
  • [3] Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis
    Ilter, E
    Karalok, H
    Tufekci, EC
    Batur, O
    CLIMACTERIC, 2006, 9 (02) : 129 - 134
  • [4] Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis
    Sebba, AI
    Bonnick, SL
    Kagan, R
    Thompson, DE
    Skalky, CS
    Chen, EL
    de Papp, AE
    CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (12) : 2031 - 2041
  • [5] Delayed-Release Risedronate (Atelvia)
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1360): : 24 - 24
  • [6] Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet
    M. R. McClung
    P. D. Miller
    J. P. Brown
    J. Zanchetta
    M. A. Bolognese
    C. L. Benhamou
    A. Balske
    D. E. Burgio
    J. Sarley
    L. K. McCullough
    R. R. Recker
    Osteoporosis International, 2012, 23 : 267 - 276
  • [7] Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet
    McClung, M. R.
    Miller, P. D.
    Brown, J. P.
    Zanchetta, J.
    Bolognese, M. A.
    Benhamou, C. L.
    Balske, A.
    Burgio, D. E.
    Sarley, J.
    McCullough, L. K.
    Recker, R. R.
    OSTEOPOROSIS INTERNATIONAL, 2012, 23 (01) : 267 - 276
  • [8] Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
    Casado, Enrique
    Rosas, Jose
    Rubio-Terres, Carlos
    Rubio-Rodriguez, Dario
    Boolell, Mitra
    Aristegui, Ignacio
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (11)
  • [9] COST-EFFECTIVENESS OF WEEKLY GASTRO-RESISTANT RISEDRONATE 35 MG, COMPARED WITH WEEKLY ALENDRONATE TABLETS, IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS IN SPAIN
    Casado, E.
    Rosas, J. C.
    Aristegui, I.
    Rubio-Terres, C.
    Rubio-Rodriguez, D.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S333 - S333
  • [10] Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years
    Bonnick, Sydney
    Saag, Kenneth G.
    Kiel, Douglas P.
    McClung, Michael
    Hochberg, Marc
    Burnett, Sherri-Ann M.
    Sebba, Anthony
    Kagan, Risa
    Chen, Erluo
    Thompson, Desmond E.
    de Papp, Anne E.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (07): : 2631 - 2637